Transcatheter Pulmonary Valve Replacement and Catheter Ablation of Ventricular Tachycardia in Tetralogy of Fallot
Patients with TOF that are referred for transcatheter PVR may harbor undiagnosed substrates for sustained monomorphic or polymorphic VT irrespective of their baseline SCD risk. We hypothesize that the combination of VT circuit elimination and favorable reverse remodeling following PVR may operate synergistically to reduce the risk for sustained MVT and SCD for patients with TOF, avoiding the need for alternative therapies. The present study aims to evaluate risk reduction for patients with TOF undergoing transcatheter PVR by performing electrophysiological studies with catheter ablation of demonstrated potential VT substrates prior to transcatheter PVR.
Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression R33
~60 subjects with MDD will undergo MRI scanning during t-PBM (administered with an irradiance of 291.7 mW/cm2 for 333s) before and after a randomized, double-blinded, controlled 16-session course of treatment with t-PBM or sham. t-PBM will be administered via NeuroThera’s LightForce® EXPi Deep Tissue Laser TherapyTM System, Transcranial PhotoBioModulation-1000 (tPBM-2.0).
Transcranial Photobiomodulation for Alzheimer's Disease
This multi-site study will be the first to evaluate the dose-dependent effects of t-PBM in amnestic Mild Cognitive Impairment (aMCI) and early Alzheimer’s Disease (AD) (CDR of 0.5-1, FAST 1-4; age 65-85) in a randomized clinical trial of 8 weeks of t-PBM vs. sham. At baseline, all subjects will complete initial neuropsychological testing. To elucidate mechanisms of action of t-PBM, prior to treatment, subjects will undergo neuroimaging related to critical features of AD: tau 18F MK-6240 load (PET), measures of brain bioenergetics (31P-MRS), and functional connectivity (rs-fMRI). After undergoing target engagement testing (t-PBM session performed during fMRI to detect BOLD changes with active t-PBM), subjects will then be randomized to t-PBM/sham. Subjects will then complete 24 t-PBM/sham treatments, ~6 min per day, 3 days per week, for 8 weeks. t-PBM will be administered via continuous, 808 nm wavelength laser delivery to the forehead bilaterally (at standard EEG electrode positions F4, F3).
Transforming Tisch Hospital | NYU Langone Health
Tisch Hospital is undergoing a renovation that is a key component of the larger NYU Langone campus transformation.
Transgender Health | NYU Langone Health
At NYU Langone, we provide care for transgender and nonbinary adults and adolescents, including gender-affirming surgery and hormone therapy.
Transgender Health Doctors | NYU Langone Health
Find a doctor at the Transgender Health at NYU Langone.
Transgender Youth Health Program | NYU Langone Health
Experts at Hassenfeld Children’s Hospital at NYU Langone’s Transgender Youth Health Program provide medical care and psychosocial support.
Transition Services for Women with Disabilities | NYU Langone Health
NYU Langone’s Initiative for Women with Disabilities helps women as they transition from adolescence to adulthood.
Transplantation & Cellular Therapy Center | NYU Langone Health
Perlmutter Cancer Center’s Transplantation and Cellular Therapy Center offers outpatient blood and marrow transplants to treat blood cancers.
Transplantation & Cellular Therapy Center—Long Island | NYU Langone Health
Perlmutter Cancer Center’s Transplantation and Cellular Therapy Center—Long Island offers outpatient blood and marrow transplants to treat blood cancers.